Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CCNC | P24863 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.50 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.49 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.49 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910411 | 0.88 | GPR35 (0.49) | PARP1MAPTTXNRD1TXNRD3TXNRD2 | |
| SCHEMBL16289937 | 0.80 | PARP1 (0.53) | PARP1MAPTL3MBTL1CCNCCDK8 | |
| SCHEMBL30349874 | 0.80 | L3MBTL1 (0.54) | PARP1L3MBTL1CCNCCDK8TXNRD1 | |
| SCHEMBL6202198 | 0.80 | NR4A2 (0.53) | PARP1L3MBTL1CCNCCDK8TXNRD1 | |
| SCHEMBL22492337 | 0.80 | PARP1 (0.53) | PARP1MAPTL3MBTL1CCNCCDK8 | |
| SCHEMBL537824 | 0.80 | PARP1 (0.53) | PARP1MAPTL3MBTL1CCNCCDK8 | |
| SCHEMBL4642829 | 0.80 | L3MBTL1 (0.54) | PARP1L3MBTL1CCNCCDK8TXNRD1 | |
| SCHEMBL31067263 | 0.80 | PARP1 (0.53) | PARP1MAPTL3MBTL1CCNCCDK8 | |
| SCHEMBL30175863 | 0.80 | LMNA (0.55) | PARP1MAPTL3MBTL1CCNCCDK8 | |
| SCHEMBL31040685 | 0.78 | TXNRD1 (0.58) | PARP1MAPTL3MBTL1TXNRD1TXNRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106432206-A | Method for synthesizing lapatinib or intermediate 5-(4-hydroxy quinazoline)-furan-2-formaldehyde of lapatinib | 成都美睿科生物科技有限公司 | 2017-02-22 | — | — | CN | claimed |
| US-12281080-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2025-04-22 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| CN-113416166-B | Method for preparing 4-hydroxyquinoline-2 (1H) -ketone compound | 浙江外国语学院 | 2022-08-05 | — | — | CN | disclosed |
| US-20210276956-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-09-09 | — | — | US | disclosed |
| US-11014906-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200062728-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-02-27 | — | — | US | disclosed |
| CN-108373452-A | A kind of preparation method of lapatinib key intermediate | 安庆奇创药业有限公司 | 2018-08-07 | — | — | CN | disclosed |
| CN-101742908-A | therapeutic pyrazoloquinoline derivatives | HELICON THERAPEUTICS INC | 2010-06-16 | — | — | CN | disclosed |
| EP-2166852-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | Helicon Therapeutics, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008154438-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1981341-A2 | INHIBITORS OF FATTY ACID SYNTHASE (FAS) | Merck and Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080045538-A1 | Nitro and amino substituted topoisomerase agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-02-21 | — | — | US | disclosed |
| WO-2007089634-A2 | INHIBITORS OF FATTY ACID SYNTHASE (FAS) | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-6992089-B2 | Nitro and amino substituted topoisomerase agents | RUTGERS, THE UNIVERSITY OF NEW JERSEY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040102443-A1 | Nitro and amino substituted topoisomerase agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2004-05-27 | — | — | US | disclosed |
| WO-2004014906-A2 | NITRO AND AMINO SUBSTITUTED DIBENZONAPHTHYRIDINES AS TOPOISOMERASE AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | PARP1 2894/4885MAPT 3999/4885L3MBTL1 2256/4885 |
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | GABRA5, GABRB1, GABRB2 | PARP1 4637/4885MAPT 461/4885L3MBTL1 4695/4885 |
| US-20200062728-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | CDK8, CDK9, CDK19 | PARP1 636/4885MAPT 2574/4885L3MBTL1 1942/4885 |
| US-20080045538-A1 | Nitro and amino substituted topoisomerase agents | TOP1, TOP2A, TOP2B | PARP1 73/4885MAPT 4024/4885L3MBTL1 3087/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | PARP1 2205/4885MAPT 3976/4885L3MBTL1 3768/4885 |
| US-11014906-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | CDK8, CDK9, CDK19 | PARP1 566/4885MAPT 2326/4885L3MBTL1 2002/4885 |
| US-20040102443-A1 | Nitro and amino substituted topoisomerase agents | TOP1, TOP2A, TOP2B | PARP1 49/4885MAPT 4283/4885L3MBTL1 2625/4885 |
| US-12281080-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | CDK8, CDK9, CDK19 | PARP1 566/4885MAPT 2326/4885L3MBTL1 2002/4885 |
| US-20210276956-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | CDK8, CDK9, CDK19 | PARP1 636/4885MAPT 2574/4885L3MBTL1 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.